Q4 EPS Estimate for Thermo Fisher Scientific Cut by Analyst

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Research analysts at Leerink Partnrs decreased their Q4 2026 earnings per share estimates for Thermo Fisher Scientific in a note issued to investors on Thursday, July 17th. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $6.95 per share for the quarter, down from their previous estimate of $7.12. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm's quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the company earned $5.11 EPS.

Several other research analysts have also weighed in on the company. Evercore ISI dropped their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Robert W. Baird decreased their target price on Thermo Fisher Scientific from $573.00 to $553.00 and set an "outperform" rating for the company in a research note on Friday. Finally, Barclays decreased their target price on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a research note on Tuesday, June 24th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $599.30.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded down $9.60 during trading on Monday, reaching $405.15. The stock had a trading volume of 2,730,401 shares, compared to its average volume of 2,025,880. Thermo Fisher Scientific has a one year low of $385.46 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The stock has a market cap of $152.94 billion, a PE ratio of 18.94, a P/E/G ratio of 2.21 and a beta of 0.77. The firm's 50 day moving average price is $410.38 and its two-hundred day moving average price is $472.32.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of hedge funds have recently added to or reduced their stakes in TMO. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $25,000. CBIZ Investment Advisory Services LLC lifted its holdings in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after buying an additional 33 shares during the last quarter. Ameriflex Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $30,000. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter valued at $30,000. Finally, Keystone Global Partners LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter valued at $31,000. 89.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president directly owned 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. Thermo Fisher Scientific's payout ratio is currently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.